Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Matthew J. Matasar, Myron S. Czuczman, Maria Alma Rodriguez, Michael Fennessy, Thomas C. Shea, Gary Spitzer, Izidore S. Lossos, Mohamed A. Kharfan-Dabaja, Robin Joyce, Luis Fayad, Kristen Henkel, Qiming Liao, Klaus Edvardsen, Roxanne C. Jewell, Doug Fecteau, Rajendra P. Singh, Steen Lisby, Craig H. Moskowitz

Blood (2013) 122 (4): 499–506.

https://doi.org/10.1182/blood-2012-12-472027

Published: 2013

Journal Articles

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

Richard R. Furman, MD, Herbert Eradat, MD, MS, Christine Gabriella DiRienzo, BS, PhD, Suzanne R Hayman, MD, Craig C. Hofmeister, MD, Nathalie A. Avignon, BA, John P. Leonard, MD, Morton Coleman, MD, Ranjana Advani, MD, Julie C. Switzky, RN, MSN, MBA, Qiming Liao, PhD, Damini N. Shah, Steen Lisby, MD, DMSc, Thomas S Lin, MD, PhD

Blood (2011) 118 (21): 3701.

https://doi.org/10.1182/blood.V118.21.3701.3701

Published: 2011

Journal Articles

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

Matthew J. Matasar, MD, MS, Myron S. Czuczman, MD, Maria Alma Rodriguez, MD, Michael Fennessy, BSc, PhD, Thomas C. Shea, MD, Gary Spitzer, MD, Izidore S Lossos, MD, Mohamed A. Kharfan-Dabaja, MD, Robin Joyce, MD, Luis Fayad, MD, Qiming Liao, PhD, Klaus Edvardsen, MD, PhD, Steen Lisby, MD, DMSc, Craig H. Moskowitz, MD

Blood (2011) 118 (21): 957.

https://doi.org/10.1182/blood.V118.21.957.957

Published: 2011

Journal Articles

A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.

Richard R. Furman, MD, Herbert Eradat, MD, MS, Julie C. Switzky, RN, MSN, MBA, Suzanne R. Hayman, MD, Craig C. Hofmeister, MD, Nathalie A. Avignon, BA, John P. Leonard, MD, Morton Coleman, MD, Qiming Liao, PhD, Damini N. Shah, Stephanie Brownell-Buttich, BFA, Steen Lisby, MD, DMSC, Thomas S. Lin, MD, PhD

Blood (2010) 116 (21): 1795.

https://doi.org/10.1182/blood.V116.21.1795.1795

Published: 2010

NARROW

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only